{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:28:05Z","timestamp":1759692485542,"version":"3.41.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T00:00:00Z","timestamp":1467590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"No funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00228-016-2085-2","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T09:01:30Z","timestamp":1467622890000},"page":"1091-1098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetic patterns of risperidone-associated adverse drug reactions"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen R. J.","family":"Schruers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Walther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Lammertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,4]]},"reference":[{"issue":"2","key":"2085_CR1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","volume":"244","author":"PA Janssen","year":"1988","unstructured":"Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244(2):685\u2013693","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2085_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O\u2019Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15(1):1\u201344. doi: 10.1111\/bdi.12025","journal-title":"Bipolar Disord"},{"key":"2085_CR3","doi-asserted-by":"publisher","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, Antony, MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O\u2019Connor K, Rabheru K, Richter, PM, Robichaud M, Walker JR Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles a, McGill U (2014) Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 14 Suppl 1:S1. doi: 10.1186\/1471-244X-14-S1-S1","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"2085_CR4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","volume":"359","author":"J Fang","year":"1999","unstructured":"Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3\u00a0A4. Naunyn Schmiedeberg\u2019s Arch Pharmacol 359:147\u2013151","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"6","key":"2085_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/0091270009347867","volume":"50","author":"Q Xiang","year":"2010","unstructured":"Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM (2010) Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50(6):659\u2013666. doi: 10.1177\/0091270009347867","journal-title":"J Clin Pharmacol"},{"issue":"Suppl","key":"2085_CR6","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. The Journal of Clinical Psychiatry 55(Suppl):13\u201317","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"6","key":"2085_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195\u2013235","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"2085_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.pnpbp.2010.02.014","volume":"34","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, Sugawara N, Sato Y, Tsuchimine S, Furukori H, Kaneko S (2010) Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 34(3):537\u2013540. doi: 10.1016\/j.pnpbp.2010.02.014","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"6","key":"2085_CR9","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","volume":"32","author":"N Yasui-Furukori","year":"2008","unstructured":"Yasui-Furukori N, Saito M, Tsuchimine S, Nakagami T, Sato Y, Sugawara N, Kaneko S (2008) Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 32(6):1491\u20131495. doi: 10.1016\/j.pnpbp.2008.05.006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"5","key":"2085_CR10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","volume":"162","author":"R Knegtering","year":"2005","unstructured":"Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ (2005) Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162(5):1010\u20131012. doi: 10.1176\/appi.ajp.162.5.1010","journal-title":"Am J Psychiatry"},{"issue":"8","key":"2085_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hup.811","volume":"21","author":"KI Melkersson","year":"2006","unstructured":"Melkersson KI (2006) Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Human Psychopharmacology 21(8):529\u2013532. doi: 10.1002\/hup.811","journal-title":"Human Psychopharmacology"},{"issue":"4","key":"2085_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","volume":"115","author":"J Eberhard","year":"2007","unstructured":"Eberhard J, Lindstrom E, Holstad M, Levander S (2007) Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 115(4):268\u2013276. doi: 10.1111\/j.1600-0447.2006.00897.x","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2085_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1745-7254.2006.00256.x","volume":"27","author":"ZL Zhou","year":"2006","unstructured":"Zhou ZL, Li X, Peng HY, Yu XY, Yang M, Su FL, Wang F, Zhu RH, Deng CY, Lin QX, Wang CY, Li WB, Lin SG, Li HD (2006) Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 27(3):381\u2013386. doi: 10.1111\/j.1745-7254.2006.00256.x","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"2085_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0269881107077357","volume":"21","author":"L Wang","year":"2007","unstructured":"Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L (2007) Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 21(8):837\u2013842. doi: 10.1177\/0269881107077357","journal-title":"J Psychopharmacol"},{"key":"2085_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","volume":"212","author":"N Ginovart","year":"2012","unstructured":"Ginovart N, Kapur S (2012) Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 212:27\u201352. doi: 10.1007\/978-3-642-25761-2_2","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"2085_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-9338(00)00536-8","volume":"16","author":"MC Mauri","year":"2001","unstructured":"Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, Papa P (2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry: J Assoc Eur Psychiatrists 16(1):57\u201363","journal-title":"Eur Psychiatry: J Assoc Eur Psychiatrists"},{"issue":"4","key":"2085_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","volume":"255","author":"M Riedel","year":"2005","unstructured":"Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255(4):261\u2013268. doi: 10.1007\/s00406-004-0556-4","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"2085_CR18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1440-1819.2003.01212.x","volume":"58","author":"PS Chen","year":"2004","unstructured":"Chen PS, Yang YK, Su SF, Liao YC, Chang JW, Yeh TL (2004) Correlation between scores on continuous performance test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci 58(2):168\u2013172","journal-title":"Psychiatry Clin Neurosci"},{"key":"2085_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000131","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Haen E, Hiemke C, Gr\u00fcnder G, Stegmann B, Schruers RJK, Vesenlinovic T, Lammertz S, Paulzen M (2016) Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? Int Clin Psychopharmacol. doi: 10.1097\/YIC.0000000000000131","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"2085_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054932","volume":"44","author":"R Yoshimura","year":"2001","unstructured":"Yoshimura R, Ueda N, Nakamura J (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44(3):129\u2013133","journal-title":"Neuropsychobiology"},{"issue":"2","key":"2085_CR21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200503000-00002","volume":"20","author":"S Kakihara","year":"2005","unstructured":"Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J (2005) Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20(2):71\u201378","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"2085_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","volume":"66","author":"N Jovanovic","year":"2010","unstructured":"Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM (2010) The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 66(11):1109\u20131117. doi: 10.1007\/s00228-010-0850-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2085_CR23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00044011-200019040-00006","volume":"19","author":"P Odou","year":"2000","unstructured":"Odou P, Levron JC, Luyckx M, Brunet C, Robert H (2000) Risperidone drug monitoring: a useful clinical tool? Clin Drug Investig 19(4):283\u2013292","journal-title":"Clin Drug Investig"},{"issue":"2","key":"2085_CR24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","volume":"153","author":"E Spina","year":"2001","unstructured":"Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153(2):238\u2013243","journal-title":"Psychopharmacology"},{"key":"2085_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1\u2013100","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"2085_CR26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","volume":"20","author":"OV Olesen","year":"1998","unstructured":"Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20(4):380\u2013384","journal-title":"Ther Drug Monit"},{"issue":"7","key":"2085_CR27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1177\/0269881109104849","volume":"24","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, Furukori H, Suzuki A, Kondo T, Kaneko S (2010) Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 24(7):987\u2013994. doi: 10.1177\/0269881109104849","journal-title":"J Psychopharmacol"},{"issue":"6","key":"2085_CR28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1292489","volume":"44","author":"E Haen","year":"2011","unstructured":"Haen E (2011) Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry 44(6):254\u2013258","journal-title":"Pharmacopsychiatry"},{"issue":"05","key":"2085_CR29","first-page":"A23","volume":"41","author":"A K\u00f6stlbacher","year":"2008","unstructured":"K\u00f6stlbacher A, Haen E (2008) Konbest\u2014a Web-based laboratory information management system (LIMS) for TDM-laboratories. Pharmacopsychiatry 41(05):A23","journal-title":"Pharmacopsychiatry"},{"key":"2085_CR30","unstructured":"US Food and Drug Administration (2014) Drug development and drug interactions: table of substrates, inhibitors and inducers. http:\/\/www.fda.gov\/Drugs\/Developmenvt-ApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm . Accessed 06\/13\/2016"},{"issue":"5","key":"2085_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","volume":"66","author":"Y Feng","year":"2008","unstructured":"Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 66(5):629\u2013639. doi: 10.1111\/j.1365-2125.2008.03276.x","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2085_CR32","first-page":"1263","volume":"29","author":"N Yasui-Furukori","year":"2001","unstructured":"Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos Biological Fate Chem 29(10):1263\u20131268","journal-title":"Drug Metab Dispos Biological Fate Chem"},{"issue":"3","key":"2085_CR33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/schbul\/22.3.475","volume":"22","author":"D Umbricht","year":"1996","unstructured":"Umbricht D, Kane JM (1996) Medical complications of new antipsychotic drugs. Schizophr Bull 22(3):475\u2013483","journal-title":"Schizophr Bull"},{"issue":"3","key":"2085_CR34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0165-1781(91)90065-W","volume":"37","author":"JA Sweeney","year":"1991","unstructured":"Sweeney JA, Keilp JG, Haas GL, Hill J, Weiden PJ (1991) Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 37(3):297\u2013308","journal-title":"Psychiatry Res"},{"issue":"2","key":"2085_CR35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004850-200015020-00003","volume":"15","author":"M Krausz","year":"2000","unstructured":"Krausz M, Moritz S, Lambert M, Naber D (2000) Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia. Int Clin Psychopharmacol 15(2):77\u201381","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"2085_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004850-200201000-00007","volume":"17","author":"S Moritz","year":"2002","unstructured":"Moritz S, Woodward TS, Krausz M, Naber D, Group PS (2002) Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. Int Clin Psychopharmacol 17(1):41\u201344","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2085_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/schbul\/sbu071","volume":"41","author":"SK Keedy","year":"2015","unstructured":"Keedy SK, Reilly JL, Bishop JR, Weiden PJ, Sweeney JA (2015) Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia. Schizophr Bull 41(2):355\u2013365. doi: 10.1093\/schbul\/sbu071","journal-title":"Schizophr Bull"},{"issue":"2","key":"2085_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","volume":"158","author":"PD Harvey","year":"2001","unstructured":"Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158(2):176\u2013184. doi: 10.1176\/appi.ajp.158.2.176","journal-title":"Am J Psychiatry"},{"issue":"10","key":"2085_CR39","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.4088\/JCP.1006e13","volume":"67","author":"PD Harvey","year":"2006","unstructured":"Harvey PD (2006) Cognitive and functional effects of atypical antipsychotic medications. J Clin Psychiatry 67(10):e13","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2085_CR40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/schbul\/sbt090","volume":"39","author":"H Takeuchi","year":"2013","unstructured":"Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H (2013) Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 39(5):993\u2013998. doi: 10.1093\/schbul\/sbt090","journal-title":"Schizophr Bull"},{"issue":"7","key":"2085_CR41","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/0269881108100777","volume":"24","author":"D Elie","year":"2010","unstructured":"Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S (2010) Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 24(7):1037\u20131044. doi: 10.1177\/0269881108100777","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2085_CR42","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/npp.2008.79","volume":"34","author":"MS Harris","year":"2009","unstructured":"Harris MS, Wiseman CL, Reilly JL, Keshavan MS, Sweeney JA (2009) Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 34(2):468\u2013476. doi: 10.1038\/npp.2008.79","journal-title":"Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol"},{"issue":"11","key":"2085_CR43","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/archpsyc.63.11.1189","volume":"63","author":"JL Reilly","year":"2006","unstructured":"Reilly JL, Harris MS, Keshavan MS, Sweeney JA (2006) Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 63(11):1189\u20131197. doi: 10.1001\/archpsyc.63.11.1189","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"2085_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/1078390309350918","volume":"16","author":"MV Seeman","year":"2010","unstructured":"Seeman MV (2010) Schizophrenia: women bear a disproportionate toll of antipsychotic side effects. J Am Psychiatric Nurses Assoc 16(1):21\u201329. doi: 10.1177\/1078390309350918","journal-title":"J Am Psychiatric Nurses Assoc"},{"issue":"5","key":"2085_CR45","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/schbul\/sbn023","volume":"35","author":"MV Seeman","year":"2009","unstructured":"Seeman MV (2009) Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 35(5):937\u2013948. doi: 10.1093\/schbul\/sbn023","journal-title":"Schizophr Bull"},{"issue":"6","key":"2085_CR46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","volume":"43","author":"S Gebhardt","year":"2009","unstructured":"Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, Hebebrand J, Theisen FM (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43(6):620\u2013626. doi: 10.1016\/j.jpsychires.2008.11.001","journal-title":"J Psychiatr Res"},{"issue":"1","key":"2085_CR47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ajp.148.1.85","volume":"148","author":"GA Keepers","year":"1991","unstructured":"Keepers GA, Casey DE (1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 148(1):85\u201389","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2085_CR48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/hup.2420","volume":"29","author":"T Cabaleiro","year":"2014","unstructured":"Cabaleiro T, Ochoa D, Lopez-Rodriguez R, Roman M, Novalbos J, Ayuso C, Abad-Santos F (2014) Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Human Psychopharmacol 29(5):459\u2013469. doi: 10.1002\/hup.2420","journal-title":"Human Psychopharmacol"},{"issue":"1","key":"2085_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.euroneuro.2014.11.011","volume":"25","author":"S Mas","year":"2015","unstructured":"Mas S, Gasso P, Ritter MA, Malagelada C, Bernardo M, Lafuente A (2015) Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacology 25(1):51\u201359. doi: 10.1016\/j.euroneuro.2014.11.011","journal-title":"Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacology"},{"issue":"1","key":"2085_CR50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","volume":"21","author":"AE Balant-Gorgia","year":"1999","unstructured":"Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 21(1):105\u2013115","journal-title":"Ther Drug Monit"},{"key":"2085_CR51","doi-asserted-by":"crossref","unstructured":"Paulzen M, Haen E, Gr\u00fcnder G, Lammertz SE, Stegmann B, Schruers RJK, Walther S, Schoretsanitis G (2016) Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients \u2013 thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol. 2016 May 31.","DOI":"10.1177\/0269881116650390"},{"issue":"3","key":"2085_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","volume":"17","author":"CF Samer","year":"2013","unstructured":"Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17(3):165\u2013184. doi: 10.1007\/s40291-013-0028-5","journal-title":"Mol Diagn Ther"},{"issue":"01","key":"2085_CR53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-2005-862617","volume":"38","author":"W Bader","year":"2005","unstructured":"Bader W, Melchner D, Nonenmacher T, Haen E (2005) Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection. Pharmacopsychiatry 38(01):4","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"2085_CR54","first-page":"142","volume":"76","author":"L Paul","year":"2009","unstructured":"Paul L, Musshoff F, Aebi B, Auw\u00e4rter V, Kr\u00e4mer T, Peters F, Skopp G, Aderjan R, Herbold M, Schmitt G (2009) Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech 76(3):142\u2013176","journal-title":"Toxichem Krimtech"},{"key":"2085_CR55","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research (2001) Guidance for industry on biomedical method validation. http:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm070107.pdf . Accessed 30 Mar 2016"},{"key":"2085_CR56","unstructured":"ICH Expert Working Group, editor. Harmonised tripartite guideline, validation of analytical procedures: test and methodology. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (1996) ICH harmonised tripartite guideline validation of analytical procedures: test and methodology. Available from http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf . Accessed 26 Apr 2016"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2085-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2085-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2085-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T23:45:01Z","timestamp":1748994301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2085-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,4]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2085-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2016,7,4]]}}}